Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s D&A?
- Denali Therapeutics Inc. (DNLI) reported D&A of $3.57M in Q2 2026.
- How has Denali Therapeutics Inc.'s D&A changed year-over-year?
- Denali Therapeutics Inc.'s D&A increased by 17.2% year-over-year, from $3.05M to $3.57M.
- What is the long-term trend for Denali Therapeutics Inc.'s D&A?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s D&A has grown at a 6.8% compound annual growth rate (CAGR), from $8.59M to $11.18M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Denali Therapeutics Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude